These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 9591856)

  • 41. Induction chemotherapy to weekly paclitaxel concurrent with curative radiotherapy in stage IV (M0) unresectable head and neck squamous cell carcinoma: a dose escalation study.
    Pergolizzi S; Adamo V; Ferraro G; Sergi C; Santacaterina A; Romeo A; De Renzis C; Zanghì M; Rossello R; Settineri N
    J Chemother; 2004 Apr; 16(2):201-5. PubMed ID: 15216957
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
    Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
    Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary site management following induction chemotherapy with cis-platinum, 5-fluorouracil, and leucovorin.
    Busse PM; Clark JR; Beard CJ; Dreyfuss AI; Lucarini JW; Rossi R; Casey D; Norris CM
    Head Neck; 1993; 15(5):413-8. PubMed ID: 8407313
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
    Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.
    Grégoire V; Beauduin M; Humblet Y; Hamoir M; Longueville J; Majois F; Remacle FM; Rousseau F; Salamon E; Wambersie A
    J Clin Oncol; 1991 Aug; 9(8):1385-92. PubMed ID: 2072142
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck.
    Uygun K; Bilici A; Karagol H; Caloglu M; Cicin I; Aksu G; Fayda M; Uzunoglu S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):601-5. PubMed ID: 19123002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
    Tishler RB; Norris CM; Colevas AD; Lamb CC; Karp D; Busse PM; Nixon A; Frankenthaler R; Lake-Willcutt B; Costello R; Case M; Posner MR
    Cancer; 2002 Oct; 95(7):1472-81. PubMed ID: 12237916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer.
    Gupta S; Khan H; Barik S; Negi MP
    Drug Discov Ther; 2013 Feb; 7(1):36-42. PubMed ID: 23524942
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Katori H; Tsukuda M; Taguchi T
    Cancer Chemother Pharmacol; 2007 May; 59(6):789-94. PubMed ID: 17053926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.
    Baghi M; Hambek M; May A; Radeloff A; Gstoettner W; Knecht R
    Anticancer Res; 2006; 26(1B):559-63. PubMed ID: 16739320
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
    Fleming GF; O'Brien SM; Hoffman PC; Vokes EE; Vogelzang NJ; Schilsky RL; Waggoner SE; Ratain MJ
    Cancer Chemother Pharmacol; 1997; 39(3):227-32. PubMed ID: 8996525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group.
    Toma S; Bonelli L; Sartoris A; Mira E; Antonelli A; Beatrice F; Giordano C; Benazzo M; Caroggio A; Cavalot AL; Gandolfo S; Garozzo A; Margarino G; Schenone G; Spadini N; Sirotovà Z; Zibordi F; Balzarini F; Serafini I; Miani P; Cortesina G
    Oncol Rep; 2004 Jun; 11(6):1297-305. PubMed ID: 15138569
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Katori H; Tsukuda M; Watai K
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
    Athanasiadis I; Taylor S; Vokes EE; Pelzer HJ; Rademaker A; Mittal BB; Ganzenko N; Blough R; Lester EP; Kies MS
    Cancer; 1997 Feb; 79(3):588-94. PubMed ID: 9028372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results.
    Zenda S; Onozawa Y; Tahara M; Kawashima M; Shikama N; Sasaki S; Boku N
    Jpn J Clin Oncol; 2007 Oct; 37(10):725-9. PubMed ID: 17925299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
    Kohno N; Kitahara S; Tamura E; Tanabe T; Nakanoboh M; Kawada M; Shirasaka T
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():592-9. PubMed ID: 10895216
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
    Brizel DM; Prosnitz RG; Hunter S; Fisher SR; Clough RL; Downey MA; Scher RL
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1418-23. PubMed ID: 15050318
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In squamous cell head and neck cancer: which platinum, how much and how often?
    Nwizu T; Adelstein DJ
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1033-9. PubMed ID: 24998393
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
    Tahara M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():167-71. PubMed ID: 16897996
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
    Colevas AD; Busse PM; Norris CM; Fried M; Tishler RB; Poulin M; Fabian RL; Fitzgerald TJ; Dreyfuss A; Peters ES; Adak S; Costello R; Barton JJ; Posner MR
    J Clin Oncol; 1998 Apr; 16(4):1331-9. PubMed ID: 9552034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.